St. Louis based spinal implant and instrument company, CoreLink, LLC, has announced the acquisition of an innovative Israeli spinal implant and product design firm, Expanding Orthopedics, Inc. (EOI).
CoreLink Acquires Israeli Spinal Implant Design Firm
1 min read Premium comments
Secondary#medicaldevice#corelink#expandingorthopedics
EOI is best known for its FLXfit articulating and expanding interbody implant. The purchase also includes a vast portfolio of patents for other expandable spinal implants.
According to the company, “CoreLink, LLC, a fast growing, vertically integrated designer and manufacturer of spinal implant systems, announced today the acquisition of the privately held Israeli medical device company Expanding Orthopedics, Inc (EOI).”
“Along with the FDA cleared expanding and articulating FLXfit and FLXfit 15 titanium TLIF interbody systems, CoreLink has also acquired a broad array of patents and in-development products addressing the expandable interbody and spinal fusion market.”
“This acquisition provides two key benefits for CoreLink and its customers: a very compelling offering in the growing expandable interbody product category and a portfolio of innovative intellectual property from which we can advance spine care,” commented Jay Bartling, CEO of CoreLink. “Combining these assets with CoreLink’s unique in-house design and manufacturing capabilities provides tremendous opportunities for us and our business partners.”
“FLXfit 15 is a unique titanium TLIF interbody device compatible with minimally invasive surgery.”
“Once in the disc space, it articulates to aid placement along the anterior aspect of the apophyseal ring, providing up to 40mm of footprint length along this critical anterior column.”
“The anterior height of the device can be continuously expanded an additional 4mm to provide up to 15° of lordosis. CoreLink will provide enhanced support for existing users of both the FLXfit and FLXfit 15 systems, while utilizing its unique vertical integration to quickly incorporate system upgrades for a full commercial re-launch in Q3.”
Jay Bartling told OTW, “EOI had an attractive IP [intellectual property] portfolio in the expanding technology space coupled with a cleared expanding interbody that we could immediately offer our customers as well as attract new opportunities. As CoreLink continues to expand both our revenue and product offering, we are pursuing appropriate acquisitions to supplement our growth strategies.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.